Melola Discovery

← Melola Discovery

Akses terbuka Jurnal

The Potential of Rosuvastatin in Stabilizing Lipid Profile and Improving Clinical Outcomes in Covid-19 Patients with Coronary Heart Disease

Nusantara Medical Science Journal · Vol. ume (2021) · hlm. 54–65

DOI
10.20956/nmsj.v6i1.12243
ISSN
2597-7288, 2460-9757
Terbit
2021-10-21
Penerbit
Faculty of Medicine, Hasanuddin University.
Bahasa
en
Lisensi
creativecommons.org/licenses/by/4.0

Abstrak

Introduction: The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge since December 2019 cause by its severe symptoms and high mortality rate. Some comorbidities are associated with clinical outcomes in COVID-19 patients, one of them is cardiovascular disease, including coronary heart disease (CHD). Statins are popularly used as the lipid controller in CHD patients. Not only controlling the lipid profile, statins also can reduce the inflammation process in COVID-19 patients. This review aims to determine the activity of statins and its potential to improve the clinical manifestation of COVID-19 patients with CHD. Methods: The method used in this paper is to examine and review the literature journal that has been published last 10 years. Results: Recent studies have shown that statins capable to control the lipid, also lowering the LDL cholesterol and increasing the HDL cholesterol. And other trials have shown that statin also have ability to reduce the inflammation and inhibit further cell damage by binding mpro, a protease produced by SARS-COV2. Conclusions: Based on those studies, we conclude that statins have the potential effect as adjuvant therapy for clinical improvement in COVID-19 patients with CHD.

Jaringan kolaborasi para penulis

11 penulis · 28 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Hasanuddin University
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
WILLIAM SUCIANGTOHasanuddin University1
Nurpudji Astuti TaslimHasanuddin University1
Suryani As’ádHasanuddin University1
Agussalim BukhariHasanuddin University1
Andi Yasmin SyaukiHasanuddin University1
Nurbaya SyamHasanuddin University1
Rima JanuaryHasanuddin University1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) https://journal.unhas.ac.id/index.php/jmednus/oai, pertama di-harvest 5 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">The Potential of Rosuvastatin in Stabilizing Lipid Profile and Improving Clinical Outcomes in Covid-19 Patients with Coronary Heart Disease</dc:title>
	<dc:creator xml:lang="en">Suciangto, William</dc:creator>
	<dc:creator xml:lang="en">Rasyid, Haerani</dc:creator>
	<dc:creator xml:lang="en">Nasrum, Nada Indira Ramadhani</dc:creator>
	<dc:creator xml:lang="en">Rahmani, Muhammad Zaki</dc:creator>
	<dc:description xml:lang="en">Introduction : The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge since December 2019 cause by its severe symptoms and high mortality rate. Some comorbidities are associated with clinical outcomes in COVID-19 patients, one of them is cardiovascular disease, including coronary heart disease (CHD). Statins are popularly used as the lipid controller in CHD patients. Not only controlling the lipid profile, statins also can reduce the inflammation process in COVID-19 patients. This review aims to determine the activity of statins and its potential to improve the clinical manifestation of COVID-19 patients with CHD. Methods : The method used in this paper is to examine and review the literature journal that has been published last 10 years. Results : Recent studies have shown that statins capable to control the lipid, also lowering the LDL cholesterol and increasing the HDL cholesterol. And other trials have shown that statin also have ability to reduce the inflammation and inhibit further cell damage by binding mpro, a protease produced by SARS-COV2. Conclusions:  Based on those studies, we conclude that statins have the potential effect as adjuvant therapy for clinical improvement in COVID-19 patients with CHD. </dc:description>
	<dc:publisher xml:lang="en">Faculty of Medicine, Hasanuddin University.</dc:publisher>
	<dc:date>2021-10-21</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:type xml:lang="en">Peer-reviewed Article</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://journal.unhas.ac.id/index.php/jmednus/article/view/12243</dc:identifier>
	<dc:identifier>10.20956/nmsj.v6i1.12243</dc:identifier>
	<dc:source xml:lang="en">Nusantara Medical Science Journal; Volume 6 Issue 1, January - June 2021; 54-65</dc:source>
	<dc:source>2597-7288</dc:source>
	<dc:source>2460-9757</dc:source>
	<dc:source>10.20956/nmsj.v6i1</dc:source>
	<dc:language>en</dc:language>
	<dc:relation>https://journal.unhas.ac.id/index.php/jmednus/article/view/12243/7432</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2021 Nusantara Medical Science Journal</dc:rights>
	<dc:rights xml:lang="en">https://creativecommons.org/licenses/by/4.0</dc:rights>
</oai_dc:dc>